Cellect Biotechnology Announces Positive Data Demonstrating Robust Engraftment Using ApoGraft was Featured in Bone Marrow Transplantation; Primary Data Points Were Submitted to the FDA During Investigational New Drug Approval Process

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals
Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals
Cellect Biotechnology Announces the ApoGraft(TM) Bone Marrow Transplantation of First Patient in U.S.
Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results
The Securities and Exchange Commission Declared Cellect Biotechnology's Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals
Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals
Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial
Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.